Cell Reports

Selective Vulnerability of Cancer Cells by Inhibition of Ca\textsuperscript{2+} Transfer from Endoplasmic Reticulum to Mitochondria

Graphical Abstract

Highlights

- Low-level ER-to-mitochondria Ca\textsuperscript{2+} flux maintains ATP levels in cells
- Absence of basal mitochondrial Ca\textsuperscript{2+} uptake induces autophagy
- Autophagy protects normal cells but is insufficient for survival of cancer cells
- Cancer cells fundamentally require basal mitochondrial Ca\textsuperscript{2+} uptake for survival

Authors

César Cárdenas, Marioly Müller, Andrew McNeal, ..., J. Alan Diehl, Todd W. Ridky, J. Kevin Foskett

Correspondence

jcesar@u.uchile.cl (C.C.), foskett@mail.med.upenn.edu (J.K.F.)

In Brief

Cárdenas et al. show that inhibition of low-level ER-to-mitochondria Ca\textsuperscript{2+} transfer is toxic, specifically to cancer cells. Their study reveals an unexpected dependency on constitutive Ca\textsuperscript{2+} transfer to mitochondria for viability of tumorigenic cells and suggest that mitochondrial Ca\textsuperscript{2+} addiction is a novel feature of cancer cells.
Selective Vulnerability of Cancer Cells by Inhibition of Ca²⁺ Transfer from Endoplasmic Reticulum to Mitochondria

César Cárdenas,1,* Marioly Müller,2 Andrew McNeal,3 Alenka Lovy,4 Fabian Jana,1 Galdo Bustos,1 Felix Urra,1 Natalia Smith,1 Jordi Molgo,6 J. Alan Diehl,6,9 Todd W. Ridky,3 and J. Kevin Foskett7,8,*

1Anatomy and Developmental Biology Program, Institute of Biomedical Sciences, Geroscience Center for Brain Health and Metabolism, University of Chile, Santiago, Chile
2Department of Medical Technology, Faculty of Medicine, University of Chile, Santiago, Chile
3Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
4Center for Neuroscience Research, Tufts University School of Medicine, Boston, MA 02111, USA
5CEA, iBiTecS, Service d’Ingénierie Moléculaire des Protéines, Laboratoire de ToxinoLOGie Moléculaire et Biotechnologies, Bâtiment 152, Courrier Number 24, 91191 Gif-sur-Yvette, France
6Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
7Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
8Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
9Present address: Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29403, USA
*Correspondence: jcesar@u.uchile.cl (C.C.), foskett@mail.med.upenn.edu (J.K.F.)

http://dx.doi.org/10.1016/j.celrep.2016.02.030
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

SUMMARY

In the absence of low-level ER-to-mitochondrial Ca²⁺ transfer, ATP levels fall, and AMPK-dependent, mTOR-independent autophagy is induced as an essential survival mechanism in many cell types. Here, we demonstrate that tumorigenic cancer cell lines, transformed primary human fibroblasts, and tumors in vivo respond similarly but that autophagy is insufficient for survival, and cancer cells die while their normal counterparts are spared. Cancer cell death is due to compromised bioenergetics that can be rescued with metabolic substrates or nucleotides and caused by necrosis associated with mitotic catastrophe during their proliferation. Our findings reveal an unexpected dependency on constitutive Ca²⁺ transfer to mitochondria for viability of tumorigenic cells and suggest that mitochondrial Ca²⁺ addiction is a feature of cancer cells.

INTRODUCTION

Inositol 1,4,5-trisphosphate receptors (InsP₃Rs) are a ubiquitous family of Ca²⁺ release channels present primarily in the ER (Foskett et al., 2007). Ca²⁺ release through the InsP₃R regulates numerous cell functions, including transcription, proliferation, secretion, and motility, among others (Cárdenas et al., 2005; Foskett et al., 2007). InsP₃R-mediated Ca²⁺ signals also regulate cell metabolism, primarily by supplying released Ca²⁺ to mitochondria, where it stimulates production of reducing equivalents by pyruvate dehydrogenase (PDH) and two Ca²⁺-dependent dehydrogenases in the tricarboxylic acid (TCA) cycle, α-ketoglutarate dehydrogenase (α-KGDH) and isocitrate dehydrogenase (IDH) (McCormack and Denton, 1979), as well as activities of respiratory chain components to promote oxidative phosphorylation (OXPHOS) and ATP production (Murphy et al., 1990; Territo et al., 2000). Low-level constitutive InsP₃R-mediated Ca²⁺ release is essential for maintaining basal levels of OXPHOS and ATP production in a wide variety of cell types (Cárdenas et al., 2010). In the absence of constitutive ER-to-mitochondrial Ca²⁺-transfer, ATP levels fall and AMPK-dependent, mTOR (mammalian target of rapamycin)-independent autophagy is induced (Cárdenas et al., 2010; Mallilankaraman et al., 2012a, 2012b) as an essential survival mechanism (Cárdenas et al., 2010). In all cell types examined, inhibition of constitutive mitochondrial Ca²⁺ uptake induced a bioenergetic crisis that resulted in a reprogramming of metabolism reminiscent of that induced by nutrient starvation, despite nutrient availability and enhanced nutrient uptake.

A hallmark feature of cancer cells is a re-programming of their metabolism, even when nutrients are available (Boroughs and DeBerardinis, 2015; Jones and Thompson, 2009; Jose et al., 2011). All major tumor suppressors and oncogenes have connections with metabolic pathways (Deberardinis et al., 2008; Koppenol et al., 2011; Levine and Puzio-Kuter, 2010; Vander Heiden et al., 2009). Warburg suggested that cancer originates from irreversible injury in mitochondria, followed by a compensatory increase of glycolysis (Warburg, 1956), but increasing evidence indicates that mitochondrial function is essential for cancer cells (Koppenol et al., 2011). A continuous supply of metabolic intermediates from the TCA cycle fuels lipid, nucleic acid, and protein biosynthesis and provides redox power essential for cancer cell proliferation (Boroughs and DeBerardinis, 2015; Deberardinis et al., 2008). Many tumor cells require...
OXPHOS to maintain growth (Birsoy et al., 2014; Caro et al., 2012) and for the majority of their ATP production (Jose et al., 2011). Mutations in OXPHOS genes are tumorigenic (Bayley and Devilee, 2010), and mitochondrial inhibitors have antitumor activity (Cheng et al., 2012; Momose et al., 2010; Zhang et al., 2014).

Accordingly, here, we asked what role constitutive mitochondrial Ca$^{2+}$ uptake, important in normal cell bioenergetics, plays in cancer cell metabolism and viability. Using tumorigenic breast and prostate cancer cell lines and genetically transformed isogenic primary human fibroblasts, we found that interruption of constitutive ER-to-mitochondrial Ca$^{2+}$ transfer elicited effects similar to those observed in normal cells, including diminished OXPHOS, AMPK activation, and induction of autophagy. Whereas autophagy was sufficient for survival of normal cells, it was insufficient in cancer cells, which responded strikingly with massive death, while their normal counterparts were spared. Furthermore, inhibition of InsP$_3$R activity strongly suppressed melanoma tumor growth in mice. Addition of metabolic substrates or nucleotides rescued the lethal effect of inhibiting mitochondrial Ca$^{2+}$ uptake, suggesting that cell death was induced by compromised bioenergetics. Cell death was caused by necrosis associated with mitotic catastrophe at daughter cell separation during ongoing proliferation of the cancer cells. Our findings reveal a fundamental and unexpected dependency on InsP$_3$R-mediated Ca$^{2+}$ transfer to mitochondria for viability of cancer cells.

RESULTS

Inhibition of InsP$_3$R Activity Creates a Bioenergetic Crisis in Both Tumorigenic and Non-tumorigenic Cell Lines

We examined the effects of InsP$_3$R inhibition on metabolic responses of human breast- and prostate-cancer-derived tumorigenic cell lines. As controls, we examined non-tumorigenic lines derived from normal tissues. XeB (5 μM, 1 hr), a specific InsP$_3$R inhibitor (Jainovich et al., 2005), reduced basal and maximal oxygen consumption rates (OCRs) (Figure 1A), enhanced AMPK phosphorylation (P-AMPK) (Figure 1B), and induced autophagic flux in both non-tumorigenic and tumorigenic breast (Figures 1C, S1A, and S1B) and prostate (Figures S2A and S2B) cell lines. The effects of XeB on bioenergetic parameters were dose dependent, with 5 μM as the minimum concentration required to strongly induce autophagy and significantly reduce basal and maximal OCRs in both MCF10A and MCF7 cells (Figures S1C-S1F). Similar responses to InsP$_3$R inhibition, including decreased OCR, increased P-AMPK, and induction of autophagy were observed in mouse melanoma B16F10 cells (Figures S2F-S2H), demonstrating that this is a non-species-specific general phenomenon. Thus, XeB generates similar bioenergetic crises in tumorigenic and non-tumorigenic cell lines. XeB inhibited constitutive and spontaneous Ca$^{2+}$ transients in both MCF10A and MCF7 cells (Figures 1D and S1G; Movie S1 [MCF7]; Movie S2 [MCF10A]). Furthermore, simultaneous genetic knockdown (KD) of InsP$_3$R types 1 and 3 (≈50%–70% efficiency; Figure S1H), the main isoforms expressed in these cells (Figures S1I–S1K), created a similar bioenergetic crisis in normal and tumorigenic cells (Figures 1E and 1F).

Inhibition of InsP$_3$R Activity Is Toxic, Specifically for Tumorigenic Cells

Breast cells were treated with XeB for 24 hr, and cell viability was assessed by flow cytometry. 2.5 μM XeB had little effect, except for tumorigenic HS578T cells, in which death was enhanced by 8% ± 1% (Figure 2A). In contrast, 5 μM XeB induced substantial death by 43% ± 4% and 53% ± 2% in tumorigenic MCF7 and T47D cell lines, respectively, and over 22% ± 1% in HS578T cells. In contrast, non-tumorigenic MCF10A cells showed only limited sensitivity (5% ± 0.4% cell death). At 10 μM, XeB killed 63% ± 7% and 64% ± 5% of MCF7 and T47D cells, respectively, and 42% ± 6% of HS578T cells, whereas MCF10A cells had only modest sensitivity (24% ± 1%) (Figure 2A). Similar XeB-mediated killing was observed in human-cancer-derived prostate cell lines PC3 and DU145, but there was little effect for the non-tumorigenic PNT2 prostate line (Figure S2C). In agreement with results from flow cytometry, XeB caused striking lactate dehydrogenase (LDH) release in all tumorigenic breast lines, compared with MCF10A cells (Figure 2B), as well as in mouse melanoma B16F10 cells (Figure S2I). As assessed by both flow cytometry and LDH release (Figures 2C and 2D), tumorigenic lines started dying as early as 6 hr of exposure to 5 μM XeB, while the non-tumorigenic cells remained insensitive. The observed differences in XeB sensitivity could not be accounted for by intrinsic differences in proliferation rates between cell lines in untreated conditions (Figures S1L and S2E). Tumorigenic breast (Figure 2E) and prostate (Figure S1D) cells exposed to XeB (5 μM for 24 hr) displayed striking morphological changes, including rounding up and shrinkage, whereas similarly treated non-tumorigenic cells maintained normal morphology.

These results suggest that tumor cell survival is dependent upon InsP$_3$R signaling. In agreement, inhibition of phospholipase C (PLC), the enzyme responsible for the generation of the InsP$_3$R ligand InsP$_3$, with U73122 (2 μM), but not the inactive analog U73343, caused striking LDH release in all tumorigenic breast cell lines, with substantially less effects in the non-tumorigenic line (Figure 2F). Similarly, simultaneous genetic KD of InsP$_3$R types 1 and 3 caused comparable LDH release as XeB and U73122 in MCF7 and T47D cells, whereas non-tumorigenic MCF10A cells showed only a small increase (Figure 2G). Thus, tumorigenic cell lines appear to have an essential dependence on InsP$_3$R-mediated Ca$^{2+}$ signaling for survival, unlike normal cells.

Inhibition of InsP$_3$R Activity Reduces the Proliferative Potential of Cancer Cell Lines

Colon cell formation is a hallmark of cancer cells that reflects their ability to proliferate indefinitely (Munshi et al., 2005). XeB (5 μM, 24 hr) diminished colony formation by tumorigenic breast MCF7 (Figure 3A) and T47D cells and prostate PC3 cells (Figures S3A and S3B). In normal cells, the bioenergetic crisis caused by inhibition of InsP$_3$R activity could be overcome by providing pyruvate as a mitochondrial substrate, presumably by mass action to drive flux through the system (Cárdenas et al., 2010). Methyl-pyruvate (5 μM, 24 hr) rescued the XeB-induced MCF7 colony formation defect (Figure 3B). Pyruvate has antioxidant properties (Andrae et al., 1985). However, XeB did not enhance reactive oxygen species (ROS) production (Figure S3C), and
N-acetylcysteine (NAC) (5 mM, 24 hr) did not rescue colony formation (Figure 3B) or prevent XeB-induced AMPK activation (Figure S3D), autophagy (Figure S3E), or MCF7 cell death (Figure S3F). These results suggest that cancer cell killing and reduction of colony formation by inhibition of InsP3R activity is a consequence of a bioenergetic crisis that can be rescued by a mitochondrial substrate, but not by an antioxidant.

XeB Induces Cell Death in Transformed, But Not Isogenic Control, Human Fibroblasts

Although the cell lines are well validated and broadly used models, the fact that the control lines are also transformed complicates the results. Therefore, we turned to an isogenic primary human fibroblast model. Primary human fibroblasts were transformed by the incorporation of oncogenic HRasG12V while bypassing retinoblastoma (Rb)-mediated G1 cell-cycle restraint by enforced expression of cyclin-dependent kinase-4 (Cdk4) (Ridky et al., 2010). This model (HrasG12V-CDK4) has classic cancer features, including invasive properties. HrasG12V-CDK4 fibroblasts showed elevated glucose consumption (Figure S3G) and lactate release (Figure S3H), consistent with acquisition of a Warburg-type metabolism. Nevertheless, control and transformed cells had comparable OCRs, suggesting similar OXPHOS (Figure 4A). Furthermore, the OCR was reduced by XeB to a similar extent in HrasG12V-CDK4 and isogenic control cells (Figure 4A), and a bioenergetic crisis ensued, as evidenced by increased P-AMPK and induction of autophagy (Figures 4B and 4C). These results suggest that mitochondria remain important for maintenance of cell bioenergetics in these primary transformed cells.

As in the cancer cell lines, XeB induced profound morphological changes and reduced the number of HrasG12V-CDK4 cells per field, whereas isogenic controls behaved similarly to vehicle-treated cells (Figure S3). LDH release was enhanced 6-fold in HrasG12V-CDK4 cells, compared with isogenic controls (Figure 4D). The sensitivity of HrasG12V-CDK4 cells compared with
that of isogenic cells could not be accounted for by differences in their normal rates of proliferation (Figure S3J). Simultaneous KD of InsP$_3$R types 1 and 3, the main isoforms in these cells (Figures S4 A–S4D) enhanced P-AMPK and autophagy in both HrasG12V-CDK4 and isogenic control fibroblasts (Figure 4 E and 4F), but it caused significant death, specifically in the HrasG12V-CDK4 cells (Figure 4G). Thus, in primary human cells, as in breast and prostate cell lines, inhibition of InsP$_3$R activity is strongly toxic specifically for cancer cells.

**Killing of Cancer Cells by Inhibition of InsP$_3$R Activity Is Mediated by Altered Mitochondrial Function**

In normal cells, inhibition of mitochondrial Ca$^{2+}$ uptake phenocopies the effects of InsP$_3$R inhibition on cell bioenergetics, suggesting that the primary role of InsP$_3$R activity in preserving normal cellular bioenergetics is to provide Ca$^{2+}$ to mitochondria (Mallilankaraman et al., 2012a). The similar bioenergetic responses to inhibition of InsP$_3$R activity of tumor cell lines and HrasG12V-CDK4 cells suggested that cancer cells may have a similar dependence on constitutive mitochondrial Ca$^{2+}$ uptake. To test this, we knocked down in HrasG12V-CDK4 and isogenic control cells the expression of MCU, the pore-forming subunit of the mitochondrial uniporter Ca$^{2+}$ channel, the major Ca$^{2+}$ uptake pathway in mitochondria (Foskett and Philipson, 2015). MCU expression was similar in human normal versus transformed fibroblasts or between the MCF10A and MCF7 cells (Figures S4 E and S4F). MCU KD (Figure S4 E) increased P-AMPK and induced autophagy (Figures 4 E and 4F), as in normal cells (Mallilankaraman et al., 2012a, 2012b). Importantly, MCU KD enhanced killing preferentially of the HrasG12V-CDK4-transformed cells (Figure 4G). In contrast, overexpression of MCU was unable to protect MCF7 cells from death induced by InsP$_3$R inhibition with XeB (Figures S4G and S4H). These results suggest that InsP$_3$R-mediated Ca$^{2+}$ release and its transfer to mitochondria through MCU are essential to maintain cancer cell viability.

**Figure 2. Inhibition of InsP$_3$R Causes Death of Tumorigenic Breast Cell Lines**

(A) Non-tumorigenic and tumorigenic human breast cell lines were treated with XeB for 24 hr, and cell death was determined by TOTO-3 incorporation by flow cytometry. $n = 3$, mean ± SEM. ***p < 0.001; NS, not significant (one-way ANOVA followed by Dunnett’s multiple comparison post test).

(B) Breast cell lines were treated with 5 µM XeB for 24 hr, and cell death was determined by LDH release. $n = 3$, mean ± SEM. *p < 0.05; ***p < 0.001 (Student’s t test).

(C) Time course of cell death determined by TOTO-3 incorporation by flow cytometry in human breast cell lines treated with 5 µM XeB. $n = 3$, mean ± SEM. *p < 0.05; ***p < 0.001 (Student’s t test).

(D) Time course of cell death determined by LDH release in breast cell lines treated with 5 µM XeB. $n = 3$, mean ± SEM. *p < 0.05; ***p < 0.001 (Student’s t test).

(E) Differential interference contrast (DIC) images of breast cell lines derived from non-tumorigenic (MCF10A) or tumorigenic (MCF7, T47D, H5578T) human tissue treated with 5 µM XeB for 24 hr. Scale bar represents 10 µm. $n = 3$.

(F) Non-tumorigenic and tumorigenic breast cell lines were treated with 2 µM of the PLC inhibitor U73122 or its inactive analog U73343 for 12 hr, and cell death was determined by LDH release. $n = 3$, mean ± SEM. ***p < 0.001; NS, not significant (Student’s t test).

(G) Cell death (LDH release) in human breast cell lines transiently transfected with a siRNA against type 1 and type 3 InsP$_3$R (IP3R KD) or a scrambled non-target (S) siRNA for 24 hr. $n = 3$, mean ± SEM. ***p < 0.001; NS, not significant (Student’s t test). See also Figure S1.
The TCA cycle is regulated by product inhibition, substrate availability, and cofactors, including Ca\(^{2+}\). PDH, IDH, and \(\alpha\)-KGDH activities are all critically regulated by mitochondrial matrix Ca\(^{2+}\) (Glancy and Balaban, 2012). Inhibition of InsP\(_3R\)-mediated Ca\(^{2+}\) release reduces PDH activity, resulting in decreased OCR and ATP production (Cárdenas et al., 2010). Cancer cells rely on mitochondria for production of TCA intermediates needed for high growth and proliferation (Boroughs and DeBerardinis, 2015). We speculated that inhibition of mitochondrial function by the absence of sufficient matrix Ca\(^{2+}\) cannot be compensated for, specifically in cancer cells, because of this dependence on the TCA cycle. Addition of dimethyl \(\alpha\)-KG or methyl-pyruvate, two substrates that energize mitochondria (Cárdenas et al., 2010; Wise and Thompson, 2010) to XeB-treated (5 \(\mu\)M, 24 hr) fibroblasts strongly reduced cell death (Figure 4H). Protection was unrelated to antioxidant properties of the substrates, since NAC (5 mM) was without effect on XeB-treated HrasG12V-CDK4 cells (Figure 5A), despite enhanced P-AMPK phosphorylation and autophagy activation (Figures 5B–5E). Thus, with nucleoside supplementation, cancer cells behave as normal cells, surviving in the face of an unfavorable bioenergetic state.

Nucleosides contribute to the purine and pyrimidine generation necessary for DNA synthesis. In normal fibroblasts, XeB (5 \(\mu\)M, 10 hr) reduced bromodeoxyuridine (BrdU) incorporation by >50% (Figure 5F), suggesting that the unfavorable bioenergetic state in the absence of Ca\(^{2+}\) transfer to mitochondria slowed cell proliferation, as expected. In marked contrast, XeB had minimal effects on BrdU incorporation into HrasG12V-CDK4 cells (Figure 5G). These results suggest that normal cells restrain entry into the S phase when conditions are unsuitable, but transformed cells do not recognize this checkpoint. Because of the enforced expression of Cdk4 in HrasG12V-CDK4 cells, it remained unclear whether other cancer cells would progress similarly into mitosis during a XeB-induced compromised bioenergetic state. XeB (5 \(\mu\)M, 24 hr) increased the population of MCF10A cells in the G1 phase that correlated with a decrease proceeding through the S phase (Figure 5H), as observed in normal human primary fibroblasts. In contrast, MCF7 cells showed no increase of the G1 population and only a slight decrease in cells in the S phase (Figure 5I). This suggests that MCF7 cells, like HrasG12V-CDK4 cells but unlike normal cells, proceed through the cell cycle, despite their compromised bioenergetic state. Similar behavior was observed in HeLa cells, a common cervical tumor cell line (Figure 5J).

HeLa cells were optically imaged to observe progression through the cell cycle. Remarkably, XeB-treated cells entered mitosis but then collapsed catastrophically and died during daughter cell separation (n = 30 mitoses) (Figure 5L; Movie S3), a phenotype never observed in vehicle-treated cells (n = 50 mitoses). This suggests that, in cells with InsP\(_3R\) activity inhibited
or mitochondrial Ca\(^{2+}\) uptake otherwise blocked, cancer cells progress through the cell cycle, despite their bioenergetic crisis, in contrast to normal cells that stop in the G1 phase, and their progression into mitosis appears to be a step that results in cell death. To probe this further, MCF7 cells were incubated with 400\(\mu\)M hydroxyurea (HU) to arrest them in the S phase of the cell cycle (Figure S5A) and then were treated with 5\(\mu\)M XeB for 24 hr. As shown in Figure 5K, the prevention of cell-cycle progression strongly decreased cell death induced by XeB.

**Cell Death Induced by Inhibition of InsP\(_{3}\)R Ca\(^{2+}\) Signaling Is Mainly Necrotic**

Our results reveal that inhibition of InsP\(_{3}\)R-mediated Ca\(^{2+}\) transfer to mitochondria causes death, specifically in tumorigenic cells, but how they die is unknown. Autophagy inhibition with 3-methyladenine (3MA) (Figures S5B and S5C) did not prevent cell death in XeB-treated MCF7 and MCF10A cells (Figure 6A) and in normal and HrasG12V-CDK4 fibroblasts (Figure 6B), suggesting that autophagy is not driving cell death. Although 3MA tended to increase cell death in XeB-treated MCF10A cells and normal fibroblasts, suggesting that autophagy plays a cell survival role, as previously suggested (Cárdenas et al., 2010), KD of ATG7 (Figures S5D and S5E) did not influence the extent of cell death (Figure S5F). Inhibition of apoptosis with the pan-caspase inhibitor Z-VAD-FMK did not protect tumorigenic cells from XeB-induced death (Figures 6A and 6B). Furthermore, western blot and immunofluorescence analyses of activated cleaved caspase-3 in human normal and HrasG12V-CDK4 fibroblasts

See also Figure S4.

---

**Figure 4. Pharmacological and Genetic Inhibition of InsP\(_{3}\)R Causes Death of Primary HrasG12V-Cdk4 Transformed Human Fibroblasts**

(A) Top: representative traces of OCR in normal (black) or transformed (red) fibroblasts treated (black circles, red upside-down triangles) or not (black squares, red triangles) with 5\(\mu\)M XeB for 1 hr. a: injection of 1\(\mu\)M oligomycin; b: 300 nM FCCP; c: 100 nM rotenone. Bottom: summary of basal and maximal OCRs in fibroblasts treated, or not treated, with 5\(\mu\)M XeB for 1 hr. n = 3, mean ± SEM. ***p < 0.001.

(B) Representative western blots of AMPK in normal (N) and transformed (T) fibroblasts treated with 5\(\mu\)M XeB (1 hr). Bar graph: P-AMPK/AMPK expressed as average fold increase over basal levels (control cells). n = 6, mean ± SEM. ***p < 0.001 (Student’s t test).

(C) Representative western blots of LC3 and tubulin in normal (N) and transformed (T) fibroblasts treated with 5\(\mu\)M XeB for 1 hr. Bar graph: LC3-II/tubulin expressed as average fold increase over basal levels (control cells). n = 6, mean ± SEM. ***p < 0.001 (Student’s t test).

(D) Determination of cell death by LDH release in normal and transformed fibroblasts treated with 2.5 or 5\(\mu\)M XeB (24 hr). n = 3, mean ± SEM. ***p < 0.001; NS, not significant (Student’s t test).

(E) Representative western blots of AMPK in normal (N) and transformed (T) fibroblasts transiently transfected with a siRNA against type 1 and type 3 InsP\(_{3}\)R (IP3R) for 24 hr or siRNA against MCU for 72 hr. Bar graph: P-AMPK/AMPK expressed as the average fold increase over basal levels (S cells). n = 3, mean ± SEM. ***p < 0.001 (Student’s t test).

(F) Representative western blots of LC3 and tubulin in normal (N) and transformed (T) fibroblasts transiently transfected with a siRNA against type 1 and type 3 InsP\(_{3}\)R for 24 hr or siRNA against MCU for 72 hr, or scrambled sRNAs (S); LC3-II/tubulin expressed as average fold increase over basal levels (S cells). n = 3, mean ± SEM. ***p < 0.001 (Student’s t test).

(G) Determination of cell death by LDH release in normal and transformed fibroblasts transiently transfected with a siRNA against type 1 and type 3 InsP\(_{3}\)R for 24 hr or siRNA against MCU for 72 hr. n = 3, mean ± SEM. ***p < 0.001 (Student’s t test).

(H) Determination of cell death by LDH release in normal and transformed fibroblasts treated simultaneously with 5\(\mu\)M XeB and either 5 mM dimethyl alpha-KG (Keto) or 5 mM b-KG (Keto) for 24 hr. n = 3, mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t test).

See also Figure S4.
(Figure S5G), and in tumor samples (Figure S5H), similarly suggested that apoptosis is not a major feature associated with cell killing. Flow cytometry analyses using fluorescein isothiocyanate (FITC)-Annexin V and propidium iodide (PI) labeling further confirmed the presence of only a small apoptotic cell population after XeB treatment (Figure S5I). Inhibition of necroptosis with necrostatin also did not prevent XeB-induced cell death (Figures 6A and 6B). The transcription factor HMGB1 is normally localized in the nucleus but is released into the cytoplasm during early stages of necrosis (Scaffidi et al., 2002). Most (>50%) MCF7 cells exposed to 5 μM XeB for 24 hr lost nuclear labeling, while untreated cells and treated MCF10A cells overwhelmingly maintained nuclear HMGB1 labeling (Figures 6C and 6D). Together with the imaging data, these results suggest that, in response to the inhibition of Ca²⁺ transfer to mitochondria, cancer cells die by necrosis, at approximately the time of daughter cell separation in mitosis.

### Inhibition of InsP₃R Activity Impairs Tumor Growth in Nude Mice

To evaluate whether InsP₃R inhibition affected tumor growth in vivo, subcutaneous tumors were generated using B16F10 cells and treated with 5 μM XeB for 24 hr after a 48-hr treatment with 400 μM HU. n = 3, mean ± SEM. **p < 0.001; NS, not significant (Student’s t test).

(L) DIC images of HeLa cells loaded with 8 nM TMRE. XeB (5 μM) was added at time 0h0'; images were collected at indicated times. Arrow shows dividing cell. Scale bar represents 10 μm.

See also Movie S3.
melanoma cells. As described earlier, treatment of B16F10 cells in vitro with 5 \( \mu \)M XeB induced AMPK phosphorylation and activated autophagy (Figures S2F and S2G). OCR was inhibited (Figure S2H), and LDH release was increased in a dose-dependent manner by a 24-hr exposure to XeB (Figure S2I). Thus, this cell line is appropriate to examine in vivo. B16F10 cells were injected subcutaneously into ventral flanks of 5- to 6-week-old nu/nu mice. When tumors were palpable, usually by day 5 post-injection, one tumoral flank was injected with 100 \( \mu \)l of a solution of 100 \( \mu \)M XeB, and the other was injected with vehicle (PBS plus ethanol). One day later, mice were euthanized, and tumors were extracted and weighed (Figure S6A, treatment 1). XeB reduced tumor size by nearly 60% in comparison to untreated tumors (Figure 7A). In a different paradigm, one tumoral flank was treated every other day for a week with 100 \( \mu \)l of a solution of 100 \( \mu \)M XeB (Figure S6A, treatment 2). XeB reduced tumor size by ~70%, compared with untreated tumors (Figure 7B). Markers of bioenergetic stress normally observed after InsP3R inhibition, including enhanced AMPK phosphorylation and autophagy, were observed in the XeB-injected tumor sections (Figures S6B and S6C). The vast majority of XeB-treated tumor cells lost HMGB1 nuclear localization, whereas control tumor cells had HMGB1 largely in the nucleus (Figure 7C). Ki67, a marker of cell proliferation, labeled nuclei equivalently in both XeB- and vehicle-treated tumors (Figure 7D), consistent with the idea that tumor cells remain committed to enter the cell cycle, even when in a state of compromised bioenergetics caused by inhibition of InsP3R activity.

DISCUSSION

The main result of the present study is the demonstration of a unique requirement of tumorigenic cancer cells for constitutive ER-to-mitochondria Ca\(^{2+}\) transfer for their survival. In the absence of this transfer, either as a consequence of blocking InsP3R-mediated Ca\(^{2+}\) release or blocking mitochondrial Ca\(^{2+}\) uptake, all tumor cells examined experienced a bioenergetic crisis similar to that of normal cells, but activation of autophagy, which enabled normal cells to survive, was insufficient, and the tumor cells died by necrosis as they proceeded through mitosis. Specific cancer cell killing was observed in human tumorigenic cell lines derived from breast, prostate, and cervix (HeLa), as well as, in data not shown, bone (143B), colon (SW480 and Colo320), kidney (RCCC), skin (WM3918, A231, WM239a, and B16F10), and brain (T98G) cancers. In addition, the same effect was observed in isogenic primary human fibroblasts transformed by expression of oncogenic Ras and enforced expression of Cdk4, a relevant combination found in spontaneous human cancers (Ridky et al., 2010). Furthermore, inhibition of InsP3R activity had strong anti-tumor efficacy in vivo.

Increased InsP3R expression and/or activity has been associated with cancer cell proliferation, growth, survival, and migration (Davis et al., 2013; Kang et al., 2010; Messai et al., 2014; Shibao et al., 2010; Shibao et al., 2011; Szatkowski et al., 2010). Furthermore, MCU is highly expressed in ER-negative and basal-like breast cancers (Serlie et al., 2006). Our results suggest that the fatal fate of cancer cells after InsP3R inhibition is a result of mitochondrial dysfunction, but it is independent of apoptotic mechanisms and, instead, appears linked to metabolic defects. Constitutive InsP3R-mediated Ca\(^{2+}\) release is essential to support activity of PDH, a key enzyme that controls the flux of carbon into the TCA cycle, through Ca\(^{2+}\)-activated PDH phosphatase activity. Consequently, diminished TCA production of NADH leads to...
lower rates of OXPHOS and a decline in ATP levels (Cárdenas et al., 2010). It is now recognized that most cancer cells rely on mitochondrial metabolism and use a significant fraction of glucose-derived pyruvate for ATP generation and for anaplerotic reactions to replenish TCA-cycle precursors for macromolecular biosynthesis (Ahn and Metallo, 2015; Jose et al., 2011; Koppenol et al., 2011; Moreno-Sánchez et al., 2007; Porporato et al., 2014). OXPHOS is important for ATP production in many cancers (Vander Heiden, 2013). Pancreatic cancer (Viale et al., 2014) and leukemic (Lagadinou et al., 2013; Nakada et al., 2010; Shi et al., 2012; Skrtić et al., 2011; Yang et al., 2011) stem cells, diffuse large B cell tumors (Caro et al., 2012), and primary glioblastoma sphere cultures (Janiszewska et al., 2012) rely on OXPHOS for survival. Primary human glioblastomas oxidize glucose via PDH and the TCA cycle during aggressive tumor growth (Marin-Valencia et al., 2012). Inhibition of complex 1 inhibits respiration and human cancer cell growth (Wheaton et al., 2014). The TCA cycle is also critically important in cancer cells for the generation of biochemical intermediates to sustain high rates of proliferation (Deberardinis et al., 2008). Most cancer cells derive lipogenic acetyl-coenzyme A (CoA) from pyruvate through Ca2+-dependent PDH (Hatzivassiliou et al., 2005; Metallo et al., 2012), and activation of PDH can promote cancer cell senescence (Kaplon et al., 2013). Some cancers have defective OXPHOS but, nevertheless, rely on the TCA cycle (Mullen et al., 2012, 2014). Even in cancer cells with mutations in the TCA cycle, the turnover of TCA cycle intermediates is maintained (Mullen et al., 2012). Most cancer cells use PDH as well as glutamine to fuel the TCA cycle (DeBerardinis et al., 2007), where it enters and then cycles through α-KGDH as the first step (Mullen et al., 2014). Importantly, α-KGDH activity is strongly Ca2+-dependent (Armstrong et al., 2014), with apparent affinity similar to that of PDH phosphatase, suggesting that it may also be reduced by interruption of ER-to-mitochondria Ca2+ transfer. Reductive carboxylation of α-KG is observed in many cancer cells with impaired OXPHOS, where it maintains levels of biosynthetic intermediates. Notably, reductive carboxylation of α-KG requires its oxidation by Ca2+-dependent α-KGDH (Mullen et al., 2014). Furthermore, reduction of α-KG to isocitrate is mediated by IDH, the other Ca2+-dependent enzyme in the TCA cycle. It is of interest that nucleotide supplementation prevented cancer cell death. α-KG is a precursor for glutamine and aspartate necessary for pyrimidine synthesis that requires mitochondrial dihydroorotate, which, in turn, requires flux through the electron transport chain (Grassian et al., 2014; Mullen et al., 2014). Together, these data suggest that cancer cells, by virtue of their reliance on OXPHOS and the TCA cycle for their viability, have a fundamental reliance on ER-to-mitochondria Ca2+ translocation of murine-melanoma-derived B16F10 cells into nude mice.

Figure 7. Inhibition of InsP3R Retards Tumor Growth In Vivo

Tumors were generated by subcutaneous injection of murine-melanoma-derived B16F10 cells into nude mice. (A) Tumor weight in mice with tumors injected with 100 μl of a 100-μM XeB solution 1 day before euthanization. n = 9, mean ± SEM. *p < 0.05 (Student’s t test). (B) Tumor weight in mice with tumors injected with 100 μl of a 100-μM XeB solution or vehicle every other day for 6 days before euthanization. n = 9, mean ± SEM. *p < 0.05 (Student’s t test). (C) HMGB1 immunofluorescence in tumors injected, or not injected, with 100 μl of a 100-μM XeB solution 1 day before euthanization. The control tumor shows strong nuclear labeling (arrows), while in the XeB-treated tumor, the nuclei appear empty (arrows), with remaining labeling cytosolic or extracellular. n = 3. Scale bar represents 10 μm. (D) K67 immunofluorescence in tumors injected, or not injected, with 100 μl of a 100-μM XeB solution 1 day before euthanization. Left: panoramic view of control and XeB-treated tumors. Scale bar represents 10 μm. Right: detail of control and XeB-treated tumors. Scale bar represents 10 μm. n = 3. See also Figure S6.
activates AMPK (Cárdenas et al., 2010; and discussed in the present study), which can phosphorylate and activate p53 to induce p21arf/cip1-mediated cell-cycle arrest (Jones et al., 2005). In contrast, proliferation of the tumor cells examined here was not slowed by inhibition of InsP3R-mediated Ca2+ signaling. MCF7 and HeLa cells have mutations in Cdk9 and Cdkn2 (http://lincs.hms.harvard.edu/) that may enable them to bypass Ca2+-regulated checkpoints. The human fibroblasts we used were transformed by introducing a constitutively active Cdk4 that phosphorylates Rb independent of Ca2+ signaling. Whereas several of the cancer cell lines have mutated p53 that could explain lack of cell-cycle arrest in response to AMPK activation by InsP3R inhibition, we examined a broad collection of cell lines with normal and mutated p53 (http://p53.free.fr/index.html), and they all displayed uninhibited cell-cycle progression. Indeed, MCF7 and HeLa cells and transformed human fibroblasts that were used for most of our studies express wild-type p53. Although AMPK can suppress the mTOR pathway, which plays a role in coordinating cell growth and the cell cycle (Cuyás et al., 2014), AMPK activation induced by InsP3R inhibition does not affect mTOR activity (Cárdenas et al., 2010). Thus, it remains unclear why proliferation was not reduced in tumorigenic cells in response to inhibition of InsP3R activity. Importantly, progression into mitosis resulted in catastrophic cell death during cytokinesis of all the tumor cells examined. Necrosis as the mechanism of cell death was confirmed by biochemical and histological markers in the cell lines, primary cells, and solid tumors. In contrast, neither apoptosis nor autophagy, nor necroptosis, appeared to play significant roles. The mechanisms that lead to mitotic catastrophic cell death (Vitale et al., 2011) around the time of cytokinesis remain to be determined. Interactions of the cyclin-dependent kinase substrate CP110 with Ca2+-binding proteins calmodulin or centrin are essential for correct cytokinesis. Whereas the presence of a CP110 mutant unable to bind calmodulin induces cytokinesis failure and multinucleated cells (Tsang et al., 2006), it is possible that cytokinesis failure in the face of a bioenergetic crisis results, instead, in necrotic mitotic catastrophe. The failure of the tumorigenic cells to slow cell proliferation, despite the fact that they were in an energetically compromised state, appears to be the major mechanism that distinguishes them from non-tumorigenic cells and accounts for their susceptibility to cell killing.

In conclusion, using a variety of different tumorigenic cell lines and isogenic primary transformed human fibroblasts, we have demonstrated that constitutive InsP3R-mediated Ca2+ transfer to mitochondria is essential in maintaining the viability of cancer cells. In the absence of this signal, normal cells restrict their entry into the cell cycle, whereas cancer cells bypass the Ca2+ checkpoint and undergo a catastrophic necrotic collapse during cytokinesis. Our results reveal a unique mitochondrial addiction to Ca2+ and a susceptibility of cancer cells that may have therapeutic implications.

**EXPERIMENTAL PROCEDURES**

**Reagents**

Antibodies were provided as follows. From Cell Signaling Technology: Phospho-α1-AMPK (Thr172), α1-AMPK, LC3B, HMBG1, ATG7, and caspase-3. From BD Biosciences: β-tubulin and InsP3R3. From Sigma: MCU. InsP3R1 antibody was provided by Dr. R.W. Neumar (University of Michigan). Secondary antibodies were conjugated with peroxidase from Amersham Biosciences. Chemicals: 3-methyladenine, methyl-pyruvate, dimethyl 2-oxoglutarate, FCCP, oligomycin, rotenone, and Hanks’ balanced salt solution were purchased from Sigma. Z-VAD-FMK and necrostatin-1 were from Tocris Bioscience. U73122 and U73343 were from Calbiochem. TOTO-3, DAPI, cleaved caspase-3 conjugated with FITC, and secondary antibodies conjugated with Alexa Fluor 488 were from Molecular Probes. Xestospongia B was extracted and purified from the marine sponge Xestospongia exigua as described previously (Cárdenas et al., 2005).

**Cell Culture and Transfection**

Details regarding cell culture and transfection are available in the Supplemental Information.

**Western Blotting and Treatments**

Details of western blotting and cell treatments are available in the Supplemental Information.

**Microscopy**

Details of microscopy are available in the Supplemental Information.

**Oxygen Consumption**

OCR was measured at 37°C using an XF24 extracellular analyzer (Seahorse Bioscience). Details are provided in the Supplemental Information.

**Clonogenic Assay**

Colony formation was assayed as described previously (Franken et al., 2006) with details provided in the Supplemental Information.

**Cell Cycle Analysis**

Details are provided in the Supplemental Information.

**Cell Death**

Cell death was determined by LDH activity release by a colorimetric assay according to the manufacturer’s instructions (Roche) and by PI (final concentration, 2.5 μg/ml) exclusion by flow cytometry (BD FACSCanto, BD Biosciences).

**Mouse Tumor Generation and Histochemistry**

All in vivo experiments were conducted with the approval of the University of Pennsylvania Institutional Animal Care and Use Committee. Murine-melanoma-derived B16F10 cells (1 × 105 cells) were subcutaneously injected into flanks of immunodeficient mice, and after 1 week, visible tumors were observed. Tumors of one flank were injected with 100 μl of a 100-μM XeB solution, and those on the contralateral side were left untreated or injected with 1% ETOH in PBS. Mice were euthanized after 1 day or 6 days of treatment with XeB, and tumors were extracted, weighed, and processed for immunohistochemistry.

**Lactate Measurements**

Cell lactate was measured colorometrically (Abcam) according to the manufacturer’s instructions.

**Glucose Uptake**

Fibroblasts were washed with Krebs-BSA buffer, pre-incubated (or not) with cytochalasin B (10 min), and incubated for 10 min at 37°C with 10 mM 2-deoxyglucose. The reaction was stopped by placing it on ice, and the samples were spun, decanted, lysed in 1% Triton X-100, and cell 2H quantified.

**Analysis and Statistics**

All data are summarized as means ± SEM; significance of differences was assessed using unpaired Student’s t tests. Differences were accepted as significant at the 95% level (p < 0.05).
SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, six figures, and three movies and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2016.02.030.

AUTHOR CONTRIBUTIONS

C.C. and J.K.F. developed the hypotheses, designed experiments, and wrote the manuscript. C.C., M.M., A.M., A.L., F.J., F.U., G.B., and N.S. contributed to experimental design and data collection. J.M. provided the purified Xestospongin B. J.A.D. provided cell lines and guidance in nude mice experimental design. T.W.R. provided normal and transformed primary human fibroblasts.

ACKNOWLEDGMENTS

We thank Dr. Chi Van Dang for helpful discussions and comments. This work was supported by NIH grants R01GM163566 (T.W.R.), R01CA163566 (T.W.R.), R01CA133154 (J.A.D.), and P50NS047243 (A.L.), FONDECYT no. 1120443 (C.C.), FONDAP no. 15150012 (C.C.), and FONDECYT postdoctoral fellowship no. 3140458 (F.J.).

Received: July 15, 2015
Revised: December 24, 2015
Accepted: February 1, 2016
Published: March 3, 2016

REFERENCES

Han, J.K., Fukushima, K., and Nuccitelli, R. (1992). Reducing inositol lipid hydrolysis, Ins(1,4,5)P3 receptor availability, or Ca2+ gradients lengthens the duration of the cell cycle in Xenopus laevis blastomeres. J. Cell Biol. 176, 147–156.


Supplemental Information

Selective Vulnerability of Cancer Cells
by Inhibition of Ca$^{2+}$ Transfer
from Endoplasmic Reticulum to Mitochondria

César Cárdenas, Marioly Müller, Andrew McNeal, Alenka Lovy, Fabian Jaña, Galdo Bustos, Felix Urra, Natalia Smith, Jordi Molgó, J. Alan Diehl, Todd W. Ridky, and J. Kevin Foskett
SUPPLEMENTARY INFORMATION

Figure S1
**Figure S2**

A-B: Western blot analysis showing P-AMPK and AMPK in PNT2 and PC3 cells treated with XeB. The Y-axis represents fold change compared to control. Stars indicate statistical significance.

C: Graph showing percentage cell death for PNT2, PC3, and DU145 cells treated with XeB at concentrations of 2.5, 5.0, and 10 [XeB]. NS indicates no significant difference.

D: Microscope images of PNT2 and PC3 cells treated with XeB, showing changes in cell morphology.

E: Graph showing cell number over time for treated cells, with NS indicating no significant difference.

F-G: Western blot analysis for LC3-I and LC3-II in B16F10 cells treated with XeB.

H: Graph showing OCR (pmol/min/µg/well) for different treatments, with significant differences indicated by ***.

I: Bar graph showing cytotoxicity percentage for B16F10 cells treated with XeB at 0, 5.0, 7.5, and 10 [XeB], with NS indicating no significant difference.
**Figure S3**

(A) Colony formation (% of control) for T47D cells.

(B) Colony formation (% of control) for PC3 cells.

(C) Images showing colony formation in MCF7 cells with different treatments.

(D) Western blot analysis of P-AMPK and AMPK in MCF7 cells.

(E) Western blot analysis of LC3-I and LC3-II in MCF7 cells.

(F) MitoSOX red fluorescence in MCF7 cells with different treatments.

(G) Glucose uptake (nmol/min/mg protein) comparison between normal (N) and transformed (T) cells.

(H) Lactate fold increase comparison between normal (N) and transformed (T) cells.

(I) Images showing cell morphology in normal and transformed cells.

(J) Cell number over time (days) for normal and transformed cells.
Figure S4
Figure S5
Figure S6
**SUPPLEMENTARY FIGURE LEGENDS**

_Figure S1. Characterization of the InsP₃R inhibitor XeB in Breast Cell Lines and the Expression of InsP₃R, related to Figure 1._

(A) Representative Westerns blots of autophagy marker LC3 or tubulin as loading control in MCF10A cell line treated with 5 µM XeB (1h) after a 6h incubation with bafilomycin A1 (Baf) and pepstatine A (PepA). Quantification of LC3-II/tubulin expressed as fold increase over basal levels (control cells). N=3, mean ± S.E., **p<0.01, ***p<0.001, NS: not significant (t-test).

(B) As in (A) using MCF7 cell line. N=3, mean ± S.E., *p<0.05, **p<0.01, ***p<0.001 (t-test).

(C) Representative Westerns blots of autophagy marker LC3 or tubulin as loading control in MCF10A cell line treated with increasing concentrations of XeB (1 h) and quantification of LC3-II/tubulin expressed as fold increase over basal levels (control cells). N=3, mean ± S.E. ***p<0.001 (one-way analysis of variance followed by Dunnett's multiple comparison post-test).

(D) As in (C) using MCF7 cell line. N=3, mean ± S.E. ***p<0.001 (one-way analysis of variance followed by Dunnett's multiple comparison post-test).

(E) Basal oxygen consumption rates (OCR) of tumorigenic and normal breast cell lines MCF10A and MCF7 incubated with increasing concentrations of XeB for 1h. N=3, mean ± S.E., *p<0.05, **p<0.01 (t-test), ***p<0.001, NS: not significant (t-test).

(F) Maximum OCR of normal MCF10A and tumorigenic MCF7 breast cell lines incubated with increasing concentrations of XeB for 1 h. N=3, mean ± S.E., *p<0.05, **p<0.01 (t-test), ***p<0.001, NS: not significant (t-test).

(G) Quantification of spontaneous Ca²⁺ release events in MCF10A and MCF7 cells treated or not with XeB. 25 cells per experiment were analyzed. N=3, mean ± S.E., NS: not significant (t-test).

(H) Non-tumorigenic (MCF10A) and tumorigenic (MCF7, T47D) breast cells transiently transfected with a siRNA against type 1 and type 3 InsP₃R or a scrambled non-target (S) siRNA for 24 hr. Bar graph: summary of expression. Protein expression was reduced by: MCF10A, type1; 67% ± 6%, type 3; 53% ± 5%; MCF7, type1; 59% ± 10%, type 3; 52% ± 7%; T47D, type1; 47% ± 7%, type 3; 61% ± 3%). N=3, mean ± S.E., **p<0.01, ***p < 0.001 (t-test).

(I) Representative Western blots of type 1 InsP₃R (IP3R1) in non-tumorigenic (MCF10A) and tumorigenic (MCF7) breast cell lines and quantification of IP3R1/tubulin expressed as relative expression compared with MCF10A. N=3, mean ± S.E., NS: not significant (t-test).

(J) Representative Western blots of type 2 InsP₃R (IP3R2) in non-tumorigenic (MCF10A) tumorigenic (MCF7) breast cell lines, and cardiomyocytes (Cardio) as a positive control. Quantification of IP3R2/tubulin expressed as relative expression compared with cardiomyocytes. N=3, mean ± S.E., NS: not significant (t-test).

(K) As in (I) for the type 3 InsP₃R (IP3R3). N=3, mean ± S.E., NS: not significant (t-test).

(L) Growth curves of non-tumorigenic and tumorigenic breast cell lines. N=3, mean ± S.E., NS: not significant (t-test).
Figure S2. Inhibition of InsP$_3$R Signaling in Human Prostate Cells and Mouse Melanoma Cells, related to Figure 2.

(A) Representative Western blots of phosphorylated (P-AMPK) and total AMPK in PNT2 (non-tumorigenic) and PC3 (tumorigenic) human prostate cells treated with 5 µM XeB for 1h. Bar graph: P-AMPK/AMPK expressed as average fold increase over basal levels (control cells). N=3, mean ± S.E. ***p<0.001 (t-test).

(B) Representative Western blots of autophagy marker LC3 or tubulin as loading control in PNT2 and PC3 cells treated with 5 µM XeB for 1h. Bar graph: quantification of LC3-II/tubulin expressed as average fold increase over basal levels (control cells). N=3, mean ± S.E., **p<0.01, ***p<0.001 (t-test).

(C) Non-tumorigenic (PNT2) and tumorigenic (PC3 and Du145) human-derived prostate cell lines were treated with increasing concentrations of XeB as indicated for 24h and cell death was determined by TOTO-3 incorporation by flow cytometry. N=3, mean ± S.E., *p<0.05, **p<0.01, *** p<0.001, NS: not significant (t-test).

(D) DIC images of normal (PNT2) or tumorigenic (PC3) cells treated with 5 µM XeB for 24h. Bar: 10 µm. N = 3.

(E) Growth curves of non-tumorigenic and tumorigenic prostate cell lines. N=3, mean ± S.E., NS: not significant (t-test).

(F) Representative Western blots of phosphorylated (P-AMPK) and total AMPK in B16F10 melanoma cells treated with 5 or 10 µM XeB for 1h. Bar graph: P-AMPK/AMPK expressed as average fold increase over basal levels (control cells). N=3, mean ± S.E., *p<0.05, **p<0.01 (t-test).

(G) Representative Western blots of autophagy marker LC3 and tubulin as loading control in B16F10 cells treated with 5 or 10 µM XeB for 1h. Bar graph: quantification of LC3-II/tubulin expressed as average fold increase over basal levels (control cells). N=3, mean ± S.E., ***p<0.001 (t-test).

(H) Basal and maximum OCR of B16F10 cells incubated with 5 or 10 µM XeB for 1h. N=3, mean ± S.E., ***p<0.001 (t-test).

(I) Cell death determined by LDH release in cells treated with increasing concentrations of XeB as indicated. N=3, mean ± S.E., ***p<0.001, NS: not significant (t-test).

Figure S3. Inhibition of InsP$_3$R Signaling Impairs Colony Formation Unrelated to Reactive Oxygen Species, and Metabolic Features of Primary Human Fibroblasts, related to Figures 3 and 4.

(A) Quantitative analysis of colony formation in tumorigenic T47D breast cell line treated or not with 5 µM XeB for 24h. N=3, mean ± S.E., ***p<0.001 (t-test).

(B) Same as in (A) in tumorigenic prostate PC3 cell line. N=3, mean ± S.E., ***p<0.001 (t-test).

(C) Top: Mitochondrial superoxide generation determined by MitoSOX red fluorescence in MCF7 cells treated with 5 µM XeB for 4h. 10 µM antimycin A (Ant-A) used as positive control. Bottom: Summary, N = 4, mean ± S.E., ***p<0.001, NS: not significant (t-test).

(D) Representative Western blots of phosphorylated (P-AMPK) and total AMPK in MCF7 cells treated with 5 µM XeB for 1h in presence or absence of 5 mM n-acetylcysteine (NAC). Bar graph: P-AMPK/AMPK expressed as average fold increase over basal levels (control cells). N=3, mean ± S.E., ***p<0.001, NS: not significant (t-test).
(E) Representative Western blots of autophagy marker LC3 or tubulin as loading control in normal fibroblasts treated with 5 µM XeB for 1h in presence or absence of 5 mM n-acetylcysteine (NAC). Bar graph: quantification of LC3-II/tubulin expressed as average fold increase over basal levels (control cells). N=3, mean ± S.E., ***p<0.001 (t-test).

(F) MCF7 cells were treated with 5 µM XeB in absence or presence of 5 mM n-acetylcysteine (NAC) for 24 for and cell death was determined by LDH release. N=3, mean ± S.E., NS: not significant, ***p<0.001 (t test).

(G) Glucose uptake in normal and transformed human fibroblasts determined radiometrically by incorporation of $^3$H-2-deoxyglucose (10 mM). N=3, mean ± S.E., **p<0.01 (t-test).

(H) Lactate generation in normal and transformed fibroblasts. N=3, mean ± S.E., ***p<0.001 (t-test).

(I) DIC images of normal and transformed fibroblasts treated with vehicle (control) or 5 µM XeB for 24h. Bar: 10 µm. N=3.

(J) Growth curves of normal and transformed fibroblasts. N=3, mean ± S.E., NS: not significant (t-test).

**Figure S4. Physiological and Metabolic Features of Primary Human Fibroblasts, related to Figure 4.**

(A) Representative Western blots of type 1 InsP$_3$R (IP3R1) in normal (N) and transformed (T) cells and quantification of IP3R1/tubulin expressed as relative expression over the normal cells. N=3, mean ± S.E., NS: not significant (t-test).

(B) Representative Western blots of type 2 InsP$_3$R (IP3R2) in normal (N) and transformed (T) cells, and cardiomyocytes (Cardio) as positive control. Quantification of IP3R2/tubulin expressed as relative expression over the cardiomyocytes. N=3, mean ± S.E., NS: not significant (t-test).

(C) As in (A) for the type 3 InsP$_3$R (IP3R3). N=3, mean ± S.E., NS: not significant (t-test).

(D) Representative Western blots of types 1 and 3 InsP$_3$R expression in normal (N) and transformed (T) fibroblasts treated or not with types 1 and 3 siRNA. Bar graph: quantification of InsP3R/tubulin expressed as relative expression to control levels in cells transfected with a scrambled non-targeting siRNA (S). InsP$_3$R protein reduced by 70 ± 2% and 69 ± 3 % for types 1 and 3, respectively in normal cells; and by 72 ± 3% and 76 ± 2 %, respectively in transformed cells 48 h after transfection compared with cells transfected with non-targeting siRNA. N=3, mean ± S.E., ***p<0.001 (t-test).

(E) Representative Western blot of MCU expression in normal (N) and transformed (T) fibroblasts. Bar graph represents MCU/tubulin relative expression compared with cells transfected with a non-targeting scrambled siRNA (S). MCU protein was reduced by 91 ± 3 % in normal and 87 ± 4 % in transformed cells 72 h post transfection. N=3, mean ± S.E., ***p<0.001 (t-test).

(F) Representative Western blots of MCU in non-tumorigenic (MCF10A) and tumorigenic (MCF7) breast cell lines and quantification of MCU/tubulin expressed as relative expression over the MCF10A cells. N=3, mean ± S.E., NS: not significant (t-test).

(G) Representative Western blots of MCU in MCF7 cell line expressing either MCU (MCU+) or the empty vector as control. Quantification of MCU/tubulin expressed as relative expression over the control. N=3, mean ± S.E., ***p<0.001 (t-test).
(H) MCU expressing (MCU+) cells and control were treated with 5 µM XeB and cell death was determined by LDH release. N=3, mean ± S.E., ***p<0.001, NS: not significant (t-test).

(I) Representative Western blots of phosphorylated (P-AMPK) and total AMPK in normal fibroblasts treated with 5 µM XeB for 1h in presence or absence of 5 mM n-acetylcysteine (NAC). Bar graph: P-AMPK/AMPK expressed as average fold increase over basal levels (control cells). N=3, mean ± S.E., ***p<0.001, NS: not significant (t-test).

(J) Representative Western blots of autophagy marker LC3 and tubulin as loading control in normal fibroblasts treated with 5 µM XeB for 1h in presence or absence of 5mM n-acetylcysteine (NAC). Bar graph: quantification of LC3-II/tubulin expressed as average fold increase over basal levels (control cells). N=3, mean ± S.E., ***p<0.001, NS: not significant (t-test).

(K) Representative Western blots of phosphorylated (P-AMPK) and total AMPK in transformed fibroblasts treated with 5 µM XeB for 1h in presence or absence of 5 mM n-acetylcysteine (NAC). Bar graph: P-AMPK/AMPK expressed as average fold increase over basal levels (control cells). N=3, mean ± S.E., ***p<0.001, NS: not significant (t-test).

(L) Representative Western blots of LC3 and tubulin in transformed fibroblasts treated with 5 µM XeB for 1h in presence or absence of 5 mM n-acetylcysteine (NAC). Bar graph: quantification of LC3-II/tubulin expressed as average fold increase over basal levels (control cells). N=3, mean ± S.E., ***p<0.001, NS: not significant (t-test).

(M) Normal and transformed fibroblasts were treated with 5 µM XeB in absence or presence of 5 mM n-acetylcysteine (NAC) for 24 and cell death was determined by LDH release. N=3, mean ± S.E., NS: not significant (t-test).

Figure S5. Autophagy and Cell Death, related to Figures 5 and 6.

(A) Cell cycle profile determined by flow cytometry in MCF7 cells treated with 400 µM hydroxyurea (HU) for 24h, showing percent of cells in each phase. N=3. ***p<0.001, NS: not significant.

(B) Representative Western blots of autophagy marker LC3 or tubulin as loading control in MCF10A cells treated with 5 µM XeB (1h) after a 6h incubation with 3-methyladenine (3MA). Quantification of LC3-II/tubulin expressed as fold increase over basal levels (control cells). N=3, mean ± S.E., ***p<0.001 (t-test).

(C) As in (B) using MCF7 cells. N=3, mean ± S.E., **p<0.01, ***p<0.001 (t-test).

(D) Representative Western blots of ATG7 expression in MCF10A cells treated with a ATG7 siRNA (KD) or a scrambled siRNA (s). Bar graph: quantification of ATG7/tubulin expressed relative to control levels in cells transfected with a non-targeting scrambled siRNA (S). ATG7 protein reduced by 59 ± 12% 48 h after transfection compared with cells transfected with non-targeting siRNA. N=3, mean ± S.E., *p<0.05 (t-test).

(E) As in (D) using MCF7 cells. N=3, mean ± S.E., **p<0.01 (t-test).

(F). Determination of cell death by propidium iodide exclusion by flow cytometry in MCF10A and MCF7 cells transiently transfected with a siRNA against ATG7 for 48h. N=3, mean ± S.E., NS: not significant (t-test).

(G). Representative Western blots of caspase 3 (Casp3) and activated caspase 3 (Cleaved casp3) in normal (N) and transformed (T) fibroblasts treated either with 5 µM XeB for 24h or 2 µM staurosporine (STA) for 6h as a positive
control. Bar graph: quantification of cleaved caspase 3/tubulin expressed as average fold increase over basal levels (control cells). N=3, mean ± S.E., *p<0.05, ***p<0.001, NS: not significant (t-test).

(H) Activated caspase 3 (green) immunofluorescence in tumors treated or not with a single injection of 100 µl of 100 µM XeB 24 hrs before euthanization. N = 3. Bar: 100 µm.

(I) Left: Flow cytometry analysis of annexinV-FITC and propidium iodide (PI) staining of apoptotic cells following 5 µM XeB treatment for 24h. Right: percentage of apoptotic cells. N=3, mean ± S.E., NS: not significant (t-test).

**Figure S6. Treatments Paradigm and Bioenergetics Stress in Tumors In Vivo, related to Figure 7.**

(A) Work flow diagram of XeB treatment of tumors in mice.

(B) Top: P-AMPK immunofluorescence in tumors treated or not with a 100 µl injection of a 100 µM XeB solution 1d before euthanization. Bar: 100 µm. Bottom: P-AMPK fluorescence intensity analysis as average fold increase over basal levels (control cells). N=3, mean ± S.E., *p<0.05 (t-test).

(C) Top: LC3 immunofluorescence in tumors treated or not with a 100 µl injection of a 100 µM XeB solution 1d before euthanization. Bar: 100 µm. Bottom: LC3 fluorescence intensity analysis as average fold increase over basal levels (control cells). N=3, mean ± S.E., ***p<0.001 (t-test).

**SUPPLEMENTARY VIDEOS**

**Supplementary Video 1, related to Figure 1.** Spontaneous cytoplasmic Ca^{2+} signals in MCF10A cells.

**Supplementary Video 2, related to Figure 1.** Spontaneous cytoplasmic Ca^{2+} signals in MCF7 cells.

**Supplementary Video 3, related to Figure 5.** HeLa cells were loaded with 8 nM TMRE and then treated with 5 µM XeB at t = 0 when time lapse recording began. Images were collected every 15 min for 8 hrs with a 63X objective. Arrow shows a dividing cell. Bar: 10 µm.

**SUPPLEMENTARY EXPERIMENTAL PROCEDURES**

**Cell Culture and Transfection**

Breast cell line MCF10A was maintained in DMEM/F12 supplemented with 5% (v/v) horse serum, 10 µg/ml insulin, 20 ng/ml EGF, 100 ng/ml cholera toxin and 0.5 µg/ml hydrocortisone. T47D, PNT2 and PC3 cell lines were maintained in RPMI, MEM and Ham’s F12K respectively, supplemented with 10% (v/v) FBS. MCF7, Du145 and HS578T cell lines were grown in DMEM supplemented with 10% (v/v) FBS. All cells were grown in the presence of 100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml fungizone (Gibco) at 37°C (95%/5% air/CO₂).
Transfections of siRNA were performed with a Nucleofector® electroporator (Amaxa Biosystems). Primary human fibroblasts were transformed by high titer LZRS retrovirus driving expression of Ras\textsuperscript{G12V} and Cdk4\textsuperscript{R24C} in the presence of 5 µg/ml polybrene as described (Ridky et al., 2010) and maintained in DMEM supplemented with 10% (v/v) FBS, 100 U/ ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml fungizone (Gibco) at 37°C (95%/5% air/CO\textsubscript{2}).

**Western Blotting and Treatments**

Drugs were added in fresh media as indicated in text or figure legends. Treatments were terminated by rapid removal of medium with cells on ice, followed by cell lysis with Cytobuster protein extraction reagent (Novagen) supplemented with protease and phosphatase inhibitors (complete PhosSTOP, Roche). Protein extracts were separated in 4%, 10% or 15% SDS-polyacrylamide gels and transferred to PDVF membranes (Millipore). Blocking was at room temperature for 1 h in 5% fat-free milk, and membranes were incubated overnight at 4°C with primary antibody, and then for 1 h at room temperature with a secondary antibody conjugated to horseradish peroxidase. Chemiluminescence detection used ECL-plus reagent (Pierce) and a series of timed exposures images were acquired with a FluorChem Q system (ProteinSimple) to ensure densitometric analyses were performed at exposures within the linear range. To ensure equal protein loading across gels, membranes were submerged in stripping buffer (Restore western blot stripping buffer; Pierce), incubated at 37°C for 20 min, and re-probed with a loading control antibody. Image J was used for densitometric analysis.

**Microscopy**

Differential contrast (DIC) and immunofluorescence imaging was performed on a Zeiss Axiovert 710 LSM ZEN confocal microscope. For time lapse microscopy, images were collected on a Nikon A1R confocal equipped with Perfect Focus in a Tokai Hit incubation chamber for 17 hours. Z-Stacks of 11 slices (1 µm intervals) were collected every 13 min. DIC and TMRE fluorescence were imaged simultaneously using a 63X plan apo lens/NA 1.4.

**Calcium Signaling**

Imaging of spontaneous changes in cytoplasmic Ca\textsuperscript{2+} concentration in MCF10A and MCF7 cells was accomplished by TIRF microscopy using a Nikon eclipse Ti inverted TIRF microscope equipped with an apo TIRF 60x, 1.49 NA lens and stage-top Tokai Hit incubator. Cells were labeled with freshly prepared Fluo-4 (5 µM) and imaged a 37°C
and 5% CO₂ at a very shallow laser angle, imaging about 100 nm into the cell. The gain on the Andor iXon EM-CCD camera was set to 300 (maximum) and images were collected every 50 ms for 2 minutes.

**Oxygen Consumption**

Cells were seeded in 24-well plates treated with CELL-TAK (BD Bioscience). After 24 h, cells were loaded into the machine for O₂ concentration determinations. Cells were sequentially exposed to oligomycin (1 µM), carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP; 300 nM) and rotenone (100 nM). After each injection, OCR was measured for 5 min, the medium was mixed and again measured for 5 min. Each time point represents average of 10 different wells. Basal OCR was calculated as difference between OCR before and after oligomycin. Maximum OCR was calculated as difference between OCR after FCCP and that measured after exposure to rotenone. Data were normalized for protein concentration by lysing samples after each experiment. In preliminary studies with each cell type, three concentrations of cells were seeded. Linear relationships between OCR and number of cells seeded were observed. The cell number was chosen that provided a nearly confluent uniform monolayer of cells. Before and at the end of each experiment, uniformity of the monolayer was evaluated by DIC microscopy.

**Clonogenic Assay**

Briefly, MCF7, T47D and PC3 cells were treated with 5 µM XeB for 24 h and then the population of cells that remained attached were trypsinized and counted. Then, one thousand cells were seeded and left undisturbed for 1 wk. Finally, colonies obtained were fixed and stained with 6% glutaraldehyde and 0.5% crystal violet, analyzed and counted.

**Growth Curves**

Breast, prostate and human fibroblast cells were plated in growth media at a density of 50,000 cells per well. Cells were counted each day using a Beckman Coulter Multisizer 4. Growth curves were performed independently at least three times.

**Cell Cycle Analysis**

Cells were cultured in 24 well plates (10⁵ cells/well) and treated or not with 5 µM XeB for 24 h. Cells were harvested, washed in PBS, permeabilized with methanol and re-suspended in 1 ml of 0.1% sodium citrate containing
0.05 mg of Propidium iodide and 50 µg of RNase for 30 min at room temperature in the dark. Flow cytometry was performed on FACS Canto (BD Biosciences), and collection and analyses of data were performed using CellQuest Software (BD Biosciences).

**Apoptosis Assessed by Flow Cytometry**

After 24h of treatment, cells were harvested, and Annexin V-FITC was added to a final concentration of 2.5 µg/ml. PI was added at a concentration of 2 µg/ml. The Annexin V-FITC and PI-labeled cells were analyzed by FACS (FACS Canto, BD Biosciences, San Jose, CA, USA).